Stabilization of hepatitis c associated collapsing focal segmental glomerulosclerosis with interferon α-2a and ribavirin

Clinical Nephrology

Volumn 80, Issue 3, 2013, Pages 231-234

  John Sperati, C ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

collapsing focal segmental glomerulosclerosis; Hepatitis C; Interferon

Indexed keywords

ANTIANEMIC AGENT; CREATININE; FUROSEMIDE; LISINOPRIL; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PEGINTERFERON ALPHA2A; RIBAVIRIN; SERUM ALBUMIN;

ADULT; ALBUMIN BLOOD LEVEL; ANEMIA; ANTIVIRAL THERAPY; ARTERIOVENOUS FISTULA; ARTICLE; BLOOD TRANSFUSION; CASE REPORT; CONCENTRATION LOSS; CREATININE BLOOD LEVEL; DISEASE ASSOCIATION; ENDOTHELIUM CELL; ERYTHROCYTE TRANSFUSION; FATIGUE; FIBROSING ALVEOLITIS; FOCAL GLOMERULOSCLEROSIS; FOOT EDEMA; GENOTYPE; HEPATITIS C; HUMAN; HYPERTENSION; INJECTION SITE CELLULITIS; INTERNATIONAL NORMALIZED RATIO; IRRITABILITY; KIDNEY BIOPSY; KIDNEY INJURY; LIVER BIOPSY; MALE; MEDICAL HISTORY; MOOD DISORDER; MYALGIA; NAUSEA; PODOCYTE; PROTEINURIA; THROMBOCYTE COUNT; TREATMENT DURATION; VIRUS LOAD; WEIGHT REDUCTION;

ANTIVIRAL AGENTS; BIOPSY; DRUG THERAPY, COMBINATION; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; HEPATITIS C; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RIBAVIRIN; TREATMENT OUTCOME;

EID: 84884515994     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/CN107337     Document Type: Article

References (16)

1. Perico N, Cattaneo D, Bikbov B, Remuzzi G. Hepatitis C infection and chronic renal diseases. Clin J Am Soc Nephrol. 2009; 4: 207-220. doi:10.2215/ CJN.03710708 PubMed
2. Albaqumi M, Barisoni L. Current views on collapsing glomerulopathy. J Am Soc Nephrol. 2008; 19: 1276-1281. doi:10.1681/ASN.2007080926 PubMed
3. Laurinavicius A, Hurwitz S, Rennke HG. Collapsing glomerulopathy in HIV and non-HIV patients: a clinicopathological and follow-up study. Kidney Int. 1999; 56: 2203-2213. doi:10.1046/j.152 3-17 55. 1999.00769.x PubMed
4. Yang AH, Lin BS, Kuo KL, Chang CC, Ng YY, Yang WC. The clinicopathological implications of endothelial tubuloreticular inclusions found in glomeruli having histopathology of idiopathic membranous nephropathy. Nephrol Dial Transplant. 2009; 24: 3419-3425. doi:10.1093/ndt/ gfp288 PubMed
5. Schaff Z, Lapis K, Keresztury S, Kolláth Z, Hérics M, Hollós I. Occurrence of tubuloreticular inclusions in acute viral hepatitis. Ultrastruct Pathol. 1982; 3: 169-173. doi:10.3109/019131282090 16 641 PubMed
6. Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB; American Association for Study of Liver Diseases. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology. 2011; 54: 1433-1444. doi:10.1002/hep.24641 PubMed
7. Rebetol R package insert. Whitehouse Station, NJ: Merck.
8. Bruchfeld A, Lindahl K, Ståhle L, Söderberg M, Schvarcz R. Interferon and ribavirin treatment in patients with hepatitis C-associated renal disease and renal insufficiency. Nephrol Dial Transplant. 2003; 18: 1573-1580. doi:10.1093/ndt/gfg209 PubMed
9. Rendina M, Schena A, Castellaneta NM, Losito F, Amoruso AC, Stallone G, Schena FP, Di Leo A, Francavilla A. The treatment of chronic hepatitis C with peginterferon alfa-2a (40 kDa) plus ribavirin in haemodialysed patients awaiting renal transplant. J Hepatol. 2007; 46: 768-774. doi:10.1016/j.jhep.2006.12.016 PubMed
10. van Leusen R, Adang RP, de Vries RA, Cnossen TT, Konings CJ, Schalm SW, Tan AC. Pegylated interferon alfa-2a (40 kD) and ribavirin in haemodialysis patients with chronic hepatitis C. Nephrol Dial Transplant. 2008; 23: 721-725. doi:10.1093/ ndt/gfm724 PubMed
11. Berenguer M. Treatment of chronic hepatitis C in hemodialysis patients. Hepatology. 2008; 48: 1690-1699. doi:10.1002/hep.22545 PubMed
12. Olson MR, Grewal KS, Bingaman A, Zaki R, Stewart S, Horton J, Araya V, Ortiz J. An international survey of the diagnosis, management, and treatment of hepatitis C in patients with end-stage renal disease. Exp Clin Transplant. 2009; 7: 203-213. PubMed
13. Ghany MG, Strader DB, Thomas DL, Seeff LB; American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009; 49: 1335-1374. doi:10.1002/hep.22759 PubMed
14. Ilyas JA, Vierling JM. An overview of emerging therapies for the treatment of chronic hepatitis C. Clin Liver Dis. 2011; 15: 515-536. doi:10.1016/j. cld.2011.05.002 PubMed
15. Markowitz GS, Nasr SH, Stokes MB, D'Agati VD. Treatment with IFN-alpha, -beta, or -gamma is associated with collapsing focal segmental glomerulosclerosis. Clin J Am Soc Nephrol. 2010; 5: 607-615. doi:10.2215/CJN.07311009 PubMed
16. Feng B, Eknoyan G, Guo ZS, Jadoul M, Rao HY, Zhang W, Wei L. Effect of interferon-alpha-based antiviral therapy on hepatitis C virus-associated glomerulonephritis: a meta-analysis. Nephrol Dial Transplant. 2011; (epub May 10, 2011). doi:10.1093/ndt/gfr236 PubMed